Urogen Pharma (URGN) Lifted to “Hold” at Zacks Investment Research

Urogen Pharma (NASDAQ:URGN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “

Several other research analysts have also recently weighed in on URGN. Oppenheimer Holdings, Inc. set a $32.00 price target on shares of Urogen Pharma and gave the stock a “buy” rating in a research note on Monday, August 14th. Jefferies Group LLC lifted their price target on shares of Urogen Pharma from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Monday, October 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $28.50.

Shares of Urogen Pharma (NASDAQ:URGN) opened at 29.21 on Wednesday. Urogen Pharma has a one year low of $13.01 and a one year high of $33.77. The company’s market cap is $379.99 million. The firm’s 50-day moving average is $28.98 and its 200-day moving average is $21.11.

ILLEGAL ACTIVITY WARNING: “Urogen Pharma (URGN) Lifted to “Hold” at Zacks Investment Research” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://ledgergazette.com/2017/10/18/urogen-pharma-urgn-lifted-to-hold-at-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in URGN. Alps Advisors Inc. bought a new stake in Urogen Pharma in the 2nd quarter valued at $195,000. LLBH Private Wealth Management LLC bought a new stake in Urogen Pharma in the 2nd quarter valued at $695,000. Spark Investment Management LLC bought a new stake in Urogen Pharma in the 2nd quarter valued at $856,000. Menora Mivtachim Holdings LTD. bought a new stake in Urogen Pharma in the 2nd quarter valued at $2,331,000. Finally, Wildcat Capital Management LLC bought a new stake in Urogen Pharma in the 2nd quarter valued at $2,439,000. Institutional investors own 36.06% of the company’s stock.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and V

According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “

Several other research analysts have also recently weighed in on URGN. Oppenheimer Holdings, Inc. set a $32.00 price target on shares of Urogen Pharma and gave the stock a “buy” rating in a research note on Monday, August 14th. Jefferies Group LLC lifted their price target on shares of Urogen Pharma from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Monday, October 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $28.50.

Shares of Urogen Pharma (NASDAQ:URGN) opened at 29.21 on Wednesday. Urogen Pharma has a one year low of $13.01 and a one year high of $33.77. The company’s market cap is $379.99 million. The firm’s 50-day moving average is $28.98 and its 200-day moving average is $21.11.

ILLEGAL ACTIVITY WARNING: “Urogen Pharma (URGN) Lifted to “Hold” at Zacks Investment Research” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://ledgergazette.com/2017/10/18/urogen-pharma-urgn-lifted-to-hold-at-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in URGN. Alps Advisors Inc. bought a new stake in Urogen Pharma in the 2nd quarter valued at $195,000. LLBH Private Wealth Management LLC bought a new stake in Urogen Pharma in the 2nd quarter valued at $695,000. Spark Investment Management LLC bought a new stake in Urogen Pharma in the 2nd quarter valued at $856,000. Menora Mivtachim Holdings LTD. bought a new stake in Urogen Pharma in the 2nd quarter valued at $2,331,000. Finally, Wildcat Capital Management LLC bought a new stake in Urogen Pharma in the 2nd quarter valued at $2,439,000. Institutional investors own 36.06% of the company’s stock.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply